MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/opth.s501953

Медицинская библиотека · Clinical ophthalmology (Auckland, N.Z.) · 2025

Five-year Outcome of Aflibercept Administration with "Treat and Extend" for Neovascular Age-Related Macular Degeneration.

Wada Iori, Oshima Yuji, Fukuda Yosuke, Shiose Satomi, Kano Kumiko, Ishikawa Keijiro, Nakao Shintaro, Kaizu Yoshihiro, Hasegawa Eiichi, Kannan Ram, Ishibashi Tatsuro, Sonoda Koh-Hei

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: This study aimed to evaluate the outcomes of aflibercept treatment using a treat-and-extend (TAE) regimen over up to 5 years in Japanese patients with neovascular age-related macular degeneration (nAMD).

PATIENTS AND

METHODS

This retrospective study included 126 consecutive treatment-naïve nAMD patients (126 eyes) who received at least three monthly intravitreal aflibercept (IVA) injections as a loading phase, followed by a treat-and-extend (TAE) regimen with follow-up for 5 years. Injection intervals were adjusted every 2 weeks and could be extended up to 16 weeks based on macular condition. Treatment was suspended if patients received 3 injections at 16-week intervals and the macula remained dry (defined as "monitoring"). Ophthalmic exams were conducted at each visit to assess disease activity.

RESULTS

The mean logarithm of the minimum angle of resolution (logMAR) best corrected visual acuity (BCVA) at baseline was 0.42 ± 0.036. Following loading injections, the mean BCVA exhibited a significant improvement. Although it subsequently declined, it sustained the initial visual acuity. The average macular thickness (CMT) was significantly reduced and maintained throughout the follow-up period. The number of aflibercept injections decreased significantly from the second year and gradually decreased during the follow-up period. Intravitreal aflibercept (IVA) treatment could be discontinued in 36 (44%) cases during the follow-up period. However, 12 of these eyes (33%) experienced recurrence. Notably, significant recurrence was observed in patients who received a higher total number of aflibercept injections. Macular atrophy was significantly more likely to occur in cases with occult macular neovascularization (MNV) with subretinal hemorrhage than in cases with other forms of nAMD.

CONCLUSION

The long-term outcomes of IVA treatment utilizing TAE regimens for nAMD in real-world practice have demonstrated favorable results, including the maintenance of visual acuity and improvement in CMT over a 5-year period.

Для цитирования: Wada Iori, Oshima Yuji, Fukuda Yosuke, Shiose Satomi, Kano Kumiko, Ishikawa Keijiro, Nakao Shintaro, Kaizu Yoshihiro, Hasegawa Eiichi, Kannan Ram, Ishibashi Tatsuro, Sonoda Koh-Hei. Five-year Outcome of Aflibercept Administration with "Treat and Extend" for Neovascular Age-Related Macular Degeneration.. Clinical ophthalmology (Auckland, N.Z.). 2025. DOI: 10.2147/opth.s501953.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.